This IP Observatory will introduce readers to some of the major contributions to the field and to the study of Intellectual Property (IP) and Intellectual Property Rights (IPRs). Listings will range from academic papers, to news articles, or even editorials which reflect and/or inform wider opinion about IP and IPRs. While this is by no means meant to be an exhaustive source of information, wehope that, as the collection builds up, this electronic resource will provide policymakers, academics and students with an important tool for better understanding national and international debates on IP and IPRs. Each publication added has been read and analysed by the Stockholm Network and a brief abstract, as well as publication review sheet, is provided with each listing. The publication review sheets are meant to give readers a quick overview of each publication and what type of IP and IPR issue they examine. Review sheets are for information purposes only and do not provide an assessment of the overall quality of any particular publication. As the Observatory is currently under construction, we would appreciate any user comments and feedback. Please email info@stockholm-network.org and we will register your comments or respond to your query.
Disclaimer
The views, findings and conclusions expressed in these publication are those of the authors and do not necessarily represent the corporate view of the Stockholm Network or those of its member think tanks.
Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence, Journal of Antimicrobial Chemotherapy, Vol. 60, No. 2, August 2007
by Theodore Kelesidis, Iosif Kelesidis, Petros I. Rafailidis, and Matthew E. Falagas (published -1)
This article examines the existence of counterfeit and substandard antimicrobial drugs and how their rapid spread and usage is having a harmful affect on the patients that use them.
Multinational Medicines – Ensuring Drug Quality in an Era of Global Manufacturing, The New England Journal of Medicine, Vol. 361, No. 8, August 20 2009
by Susan Okie (published -1)
This article examines the changing nature of drug quality issues in a globalized economy. The article looks at drug safety issues in the context of the globalization of pharmaceutical manufacturing and the growth in usage of foreign-manufactured generics in the US.
Millions at risk of prosecution in internet piracy purge, Daily Telegraph, Telegraph.co.uk, August 16 2009
by Daily Telegraph (published -1)
This article describes the apparent change in stance of the UK government towards illegal file-sharing from a relatively relaxed approach earlier this year to a more robust approach under the Business Secretary Lord Mandelson.
How to sink pirates, The Economist, November 14 2009
by The Economist (published -1)
This editorial argues that music piracy has decreased as a result of new online music services being offered through, for example, Spotify, iTunes, and Nokia Comes With Music.
Drug Marketing Exclusivity under United States and European Law, Food and Drug Law Journal, Vol. 59, Issue 4, 2004
by Valerie Junod (published -1)
This article discusses patent rights, marketing exclusivity, and data exclusivity in the United States and Europe. The article compares how the American and European legal systems have offered protection for clinical data through different lengths and mechanisms of marketing and data exclusivity.
Proposed Regulations to adjust generic balance, Managing Intellectual Property, Supplement Life Focus 2005
by David Heller and Adrian Zahl (Ridout & Maybee LLP) (published -1)
This article offers an analysis to proposed (and subsequently enforced) changes to Canadian data exclusivity and market exclusivity regulations as well as proposed amendments governing the regulation of generic drugs.
The Effect of Public Policy Initiatives on Drug Prices in Canada, Canadian Public Policy, Vol. 10, Issue 1, March 1984
by David J. Fowler and Myron J. Gordon (published -1)
This article analyses the effects of Canada’s decision in 1969 to allow the issuing of compulsory licenses for the import of patented medicines from outside Canada. The article examines the effect of this policy on the cost of medicines as well as its impact on Canadian pharmaceutical research and development.
Copyright in the age of mass digitisation, Entertainment Law Review, 17 (5), Sweet and Maxwell, 2006
by Adrian C. Laing (published -1)
This article reviews the implications of mass-scale digitisation to copyright and copyright holders. It provides a history and analysis of copyright law in Europe and the US, as well as specific case analysis.
The economic dimension of the digital challenge: a copyright perspective, Intellectual Property Quarterly, 1, Sweet and Maxwell, 2005
by Patricia Akester and Francisco Lima (published -1)
This article examines the changing nature of copyright protection in a digital age. It focuses on the difficulties internet and digital technologies present to the enforcement of copyright.
Patent Protection and Pharmaceutical R&D Spending in Canada, Canadian Public Policy, Vol. 25, No. 1, March 1999
by Bohumir Pazderka (published -1)
This article discusses the effects on corporate R&D spending of Canadian policymakers’ decision to restore full patent protection to prescription drugs in 1987 and 1992 after two decades of policies favouring compulsory licensing.
Download a review sheet and web link
